Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease A Randomized Placebo-Controlled Trial
Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease A Randomized Placebo-Controlled Trial
复制标题
DOI：
10.1164/rccm.201108-1553oc
复制
发表时间：
2012-07-01
影响因子：
24.7
通讯作者：
Brightling, Christopher E.
中科院分区：
文献类型：
--
作者：
Bafadhel, Mona;McKenna, Susan;Brightling, Christopher E.
基本原理：慢性阻塞性肺疾病（COPD）的恶化和对治疗的反应是heterogeneous.Objectives：调查血嗜酸性粒细胞的有用性，以直接皮质类固醇治疗急性加重during acquisitions.Methods：COPD急性加重的受试者进入一个随机生物标志物导向的双盲皮质类固醇与标准治疗研究。标准组的受试者接受泼尼松龙治疗2周，而在生物标志物导向组中，根据血液嗜酸性粒细胞计数生物标志物给予泼尼松龙或匹配的安慰剂。两个研究组都接受了抗生素治疗。在生物标志物导向治疗组和标准治疗组中测量血嗜酸性粒细胞以定义生物标志物阳性和阴性加重（血嗜酸性粒细胞计数>和
Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) and responses to treatment are heterogeneous.Objectives: Investigate the usefulness of blood eosinophils to direct corticosteroid therapy during exacerbations.Methods: Subjects with COPD exacerbations were entered into a randomized biomarker-directed double-blind corticosteroid versus standard therapy study. Subjects in the standard arm received prednisolone for 2 weeks, whereas in the biomarker-directed arm, prednisolone or matching placebo was given according to the blood eosinophil count biomarker. Both study groups received antibiotics. Blood eosinophils were measured in the biomarker-directed and standard therapy arms to define biomarker-positive and -negative exacerbations (blood eosinophil count > and